Compare IPST & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPST | PPCB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.7M |
| IPO Year | 2024 | 2011 |
| Metric | IPST | PPCB |
|---|---|---|
| Price | $2.56 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 249.9K | 195.3K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,402,488.00 | N/A |
| Revenue This Year | $66.82 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $0.26 | $0.06 |
| 52 Week High | $308.00 | $6.79 |
| Indicator | IPST | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 25.30 |
| Support Level | $2.18 | $0.24 |
| Resistance Level | $2.80 | $0.40 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 26.85 | 12.31 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.